Evolving Immunotherapy Approaches for Renal Cell Carcinoma

Susanna A. Curtis; Justine V. Cohen; Harriet M. Kluger

doi:10.1007/s11912-016-0542-9

Evolving Immunotherapy Approaches for Renal Cell Carcinoma

Susanna A. Curtis, Justine V. Cohen, Harriet M. Kluger

Research output: Contribution to journal › Review article › peer-review

22 Scopus citations

Abstract

Metastatic renal cell carcinoma (mRCC) continues to be associated with high rates of morbidity and mortality. Renal cell carcinoma (RCC) is typically resistant to cytotoxic chemotherapy, and while targeted therapies have activity and prolong progression-free and overall survival, responses are usually not durable. Modulating the immune system with cytokine therapy, vaccine therapy, cell therapy, and checkpoint inhibitors offers hope of prolonged survival. Standard and emerging immune therapy approaches and combinations of immune therapies and other modalities are reviewed.

Original language	English (US)
Article number	57
Journal	Current oncology reports
Volume	18
Issue number	9
DOIs	https://doi.org/10.1007/s11912-016-0542-9
State	Published - Sep 1 2016
Externally published	Yes

Keywords

Adoptive cell therapy
Cytokines
Immune checkpoint inhibitors
Immunotherapy
Renal cell carcinoma
Vaccine therapy

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11912-016-0542-9

Cite this

@article{6d7eafcdf5634ed084457d56a9f9e0fc,

title = "Evolving Immunotherapy Approaches for Renal Cell Carcinoma",

abstract = "Metastatic renal cell carcinoma (mRCC) continues to be associated with high rates of morbidity and mortality. Renal cell carcinoma (RCC) is typically resistant to cytotoxic chemotherapy, and while targeted therapies have activity and prolong progression-free and overall survival, responses are usually not durable. Modulating the immune system with cytokine therapy, vaccine therapy, cell therapy, and checkpoint inhibitors offers hope of prolonged survival. Standard and emerging immune therapy approaches and combinations of immune therapies and other modalities are reviewed.",

keywords = "Adoptive cell therapy, Cytokines, Immune checkpoint inhibitors, Immunotherapy, Renal cell carcinoma, Vaccine therapy",

author = "Curtis, {Susanna A.} and Cohen, {Justine V.} and Kluger, {Harriet M.}",

note = "Publisher Copyright: {\textcopyright} 2016, Springer Science+Business Media New York.",

year = "2016",

month = sep,

day = "1",

doi = "10.1007/s11912-016-0542-9",

language = "English (US)",

volume = "18",

journal = "Current oncology reports",

issn = "1523-3790",

publisher = "Current Science, Inc.",

number = "9",

}

TY - JOUR

T1 - Evolving Immunotherapy Approaches for Renal Cell Carcinoma

AU - Curtis, Susanna A.

AU - Cohen, Justine V.

AU - Kluger, Harriet M.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Metastatic renal cell carcinoma (mRCC) continues to be associated with high rates of morbidity and mortality. Renal cell carcinoma (RCC) is typically resistant to cytotoxic chemotherapy, and while targeted therapies have activity and prolong progression-free and overall survival, responses are usually not durable. Modulating the immune system with cytokine therapy, vaccine therapy, cell therapy, and checkpoint inhibitors offers hope of prolonged survival. Standard and emerging immune therapy approaches and combinations of immune therapies and other modalities are reviewed.

AB - Metastatic renal cell carcinoma (mRCC) continues to be associated with high rates of morbidity and mortality. Renal cell carcinoma (RCC) is typically resistant to cytotoxic chemotherapy, and while targeted therapies have activity and prolong progression-free and overall survival, responses are usually not durable. Modulating the immune system with cytokine therapy, vaccine therapy, cell therapy, and checkpoint inhibitors offers hope of prolonged survival. Standard and emerging immune therapy approaches and combinations of immune therapies and other modalities are reviewed.

KW - Adoptive cell therapy

KW - Cytokines

KW - Immune checkpoint inhibitors

KW - Immunotherapy

KW - Renal cell carcinoma

KW - Vaccine therapy

UR - http://www.scopus.com/inward/record.url?scp=84981186468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981186468&partnerID=8YFLogxK

U2 - 10.1007/s11912-016-0542-9

DO - 10.1007/s11912-016-0542-9

M3 - Review article

C2 - 27475806

AN - SCOPUS:84981186468

SN - 1523-3790

VL - 18

JO - Current oncology reports

JF - Current oncology reports

IS - 9

M1 - 57

ER -

Evolving Immunotherapy Approaches for Renal Cell Carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this